2025 n=96 / 2026 n=91
Source: Ipsos Global Oncology Monitor (Jan – Jun (H1) 2025 and Jan - Jun (H1) 2026; sampled physicians in China reporting on extensive-SCLC drug-treated patients seen in consultation. Data collected via pen and paper and then inputted into an online database. Participating physicians were primary treaters and saw a minimum number of patients per month. Cross-border I-Os are those that originate from China-International company partnerships). Data © Ipsos 2026, all rights reserved.